Bayer planning to significantly increase growth in life sciences
German drug major Bayer (BAYN: DE) is planning to significantly expand its life sciences business, aiming to achieve strong sales and earnings growth, the company said in an investor conference in Berlin.
The company seeks to considerably increase sales and margins in health care in particular through 2017, driven by recently launched pharma products and the consumer care business, which was strengthened in 2014 through acquisitions.
At the “Meet Management” investor conference in Berlin, Marijn Dekkers, chief executive of Bayer, said: “We are also optimistic for the medium term and have great plans for the Life Science businesses...We will continue to invest heavily so that we continue to be successful with innovative products.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze